Godavari Biorefineries Share News - Latest Updates, Live News & More

Latest news about Godavari Biorefineries

Godavari Biorefineries Completes IPO Proceeds Utilization with Final Monitoring Report 7 days ago

Godavari Biorefineries Limited has completed utilization of Rs. 324.91 crore from its Rs. 325.00 crore IPO proceeds, according to CARE Ratings' final monitoring report for Q3 FY26. The company reclassified Rs. 1.91 crore from issue expenses to general corporate purposes during the quarter, completing a total reclassification of Rs. 3.37 crore. Despite near-complete fund utilization, the company faces financial challenges with net losses of Rs. 23.41 crore in FY25 and Rs. 57.61 crore in H1 FY26, though management attributes these primarily to one-time tax provisions and seasonal factors.

Godavari Biorefineries Q3FY26 Results: Strong Performance with Earnings Call Recording 7 days ago

Godavari Biorefineries Receives National Green Tribunal Order for Water Treatment Implementation Feb 09, 2026

Godavari Biorefineries Partners With Synthomer for Sustainable Monomer Alternatives Feb 06, 2026

Godavari Biorefineries Limited Schedules Board Meeting on February 13, 2026 for Q3FY26 Financial Results Feb 04, 2026

More news about Godavari Biorefineries

26Dec 25

Godavari Biorefineries Clarifies Share Price Movement Under Regulation 30

Godavari Biorefineries Ltd has clarified to BSE that recent share price movements are market-driven, with no undisclosed material information or pending corporate actions. The company confirmed compliance with SEBI regulations and stated management is unaware of specific reasons for the significant price increase, attributing it to market conditions and various factors.

19Nov 25

Godavari Biorefineries Launches Princeton-Based US Subsidiary for Cancer Drug Development

Godavari Biorefineries Limited has established Sathgen Therapeutics LLC, a wholly owned subsidiary in Princeton, New Jersey, to strengthen its clinical-stage biotechnology presence in the US market. The subsidiary, led by Dr. Padmaja Ganapathy as CEO and Dr. Sendurai Mani as Chief Scientific Officer, focuses on cancer drug development, particularly triple-negative breast cancer, and global out-licensing of intellectual property. The company has secured patents in key markets and formed a Scientific Advisory Board with renowned oncology experts to guide its clinical development strategy.

17Nov 25

Godavari Biorefineries Reports 34% Revenue Growth Despite Net Loss in Q2 FY26

Godavari Biorefineries Limited (GBL) reported a 34% year-on-year increase in consolidated revenue to ₹434.30 crore for Q2 FY2026, but faced a net loss of ₹41.60 crore. The company's share price declined 1.97% to ₹256.40 following the announcement. GBL is progressing with a 200 KLPD distillery commissioning and advancing its anti-cancer research program. The company's recent Sustainability Report highlighted its focus on renewable energy, with 84% of total energy sourced from renewables in FY 2024-25, and implementation of Zero Liquid Discharge facilities at its plants.

10Nov 25

Godavari Biorefineries Launches Innovative CO2-to-DME Project, Wins Industry-Academia Partnership Award

Godavari Biorefineries Limited (GBL) has initiated a pilot project with the Institute of Chemical Technology (ICT) Mumbai to convert 450 metric tons of CO2 daily into Dimethyl Ether (DME), a clean-burning fuel. The project aims to reduce greenhouse gas emissions and promote sustainable fuel production. GBL and ICT Mumbai received the K.V. Mariwala Award for Effective Chemical Industry-Academia Partnership for 2024. The initiative could contribute to India's energy transition goals, boost farmer incomes, and position India as a leader in sustainable technology.

16Oct 25

Godavari Biorefineries Secures US and European Patents for Promising Anti-Cancer Compounds

Godavari Biorefineries, an Indian biorefinery company, has obtained patents in the US and Europe for innovative anti-cancer compounds. These compounds target uncontrolled cell growth and cancer stem cells, showing potential in treating breast and prostate cancer. The patents mark a significant step in cancer research, though further studies and clinical trials may be necessary to fully realize the compounds' potential.

22Sept 25

Godavari Biorefineries Clinches ICC Award for Groundbreaking Industry-Academia Partnership

Godavari Biorefineries Limited (GBL) and the Institute of Chemical Technology (ICT), Mumbai, received the ICC – K. V. Mariwala Award for Effective Chemical Industry–Academia Partnership. The recognition is for their collaborative development of a technology converting CO₂ into di-methyl ether (DME) using a single-step catalytic process. This method is more efficient and cost-effective than traditional approaches. GBL utilizes biogenic CO2 from ethanol fermentation for DME production, aligning with its commitment to renewable chemistry and circular economy principles.

19Sept 25

Godavari Biorefineries Clinches ICC Award for Groundbreaking CO₂ Conversion Technology

Godavari Biorefineries Ltd (GBL) has received the ICC - K. V. Mariwala Award for Effective Chemical Industry Academia Partnership from the Indian Chemical Council. The award recognizes GBL's development of a technology that converts biogenic CO₂ from ethanol fermentation into di-methyl ether (DME) through a single-step catalytic process. This innovation, created in collaboration with the Institute of Chemical Technology (ICT), Mumbai, offers a clean fuel alternative and chemical feedstock. The technology shows potential for negative carbon intensity and is scalable for industrial use.

18Aug 25

Godavari Biorefineries Reports Q1 FY26 Turnaround with Positive EBITDA and Strategic Expansion Plans

Godavari Biorefineries Limited (GBL) reported improved Q1 FY26 results with revenue at INR 533.20 crores, up from INR 522.50 crores in Q1 FY25. The company achieved a positive EBITDA of INR 6.50 crores, reversing previous losses. Bio-based chemical segment EBITDA increased by 43%. GBL is expanding its ethanol production with a new 200 KLD grain-based distillery. The company projects 3x EBITDA growth from FY25 to FY29, driven by bio-based specialty chemicals and ethanol capacity expansion. GBL also made progress in drug discovery, receiving European and Chinese patents for anti-cancer compounds.

15Aug 25

Godavari Biorefineries Secures Prestigious ICC K.V. Mariwala Award for 2024

Godavari Biorefineries Ltd. (GBL) has been awarded the ICC K.V. Mariwala Award for Effective Chemical Industry-Academia Partnership for 2024, in collaboration with the Institute of Chemical Technology Mumbai. The award, recognizing outstanding achievements in industry-academia relationships, will be presented at the ICC Awards Presentation Function on September 19, 2025. This accolade highlights GBL's commitment to fostering innovation through partnerships in the chemical sector.

11Aug 25

Godavari Biorefineries Reports Turnaround in Q1 with Improved EBITDA

Godavari Biorefineries Limited reported improved Q1 financials with total income reaching Rs. 534.00 crores, up 2% YoY. EBITDA turned positive at Rs. 6.50 crores, compared to a negative Rs. 9.50 crores last year. Ethanol segment revenue grew 51% to Rs. 205.40 crores. The company is expanding ethanol capacity and focusing on bio-based and specialty chemicals. Net loss narrowed to Rs. 16.00 crores from Rs. 26.10 crores YoY. Godavari Biorefineries aims for 3X EBITDA growth by FY29 from FY25 levels, planning to invest Rs. 325.00 crores in growth initiatives.

07Aug 25

Godavari Biorefineries Reports Mixed Q1 Results with Revenue Growth but Losses Continue

Godavari Biorefineries reported Q1 total income of Rs. 534.00 crores, up 1.7% year-over-year. EBITDA improved to Rs. 6.50 crores from negative Rs. 9.50 crores last year. Loss after tax narrowed to Rs. 16.00 crores from Rs. 26.10 crores. Bio-Based Chemicals segment showed 43% YoY EBITDA growth. Ethanol production increased to 26,057 KL. The company secured European and Chinese patents for anti-cancer compounds.

22Jul 25

Godavari Biorefineries Secures Chinese Patent for Breakthrough Anti-Cancer Molecule

Godavari Biorefineries Limited has obtained a patent in China for HYDROXY-1,4-NAPHTHALENEDIONE, a novel anti-cancer molecule. The compound, developed by the company's biotech division Sathgen Therapeutics, has shown promise in inhibiting cancer and cancer stem cells during in vitro studies, particularly against breast and prostate cancer. This patent strengthens the company's intellectual property portfolio in the Chinese market and represents a significant step in its pharmaceutical endeavors.

16Jul 25

Godavari Biorefineries Secures Chinese Patent for Promising Cancer Treatment Compound

Godavari Biorefineries has been granted a patent by the China National Intellectual Property Administration for a compound showing promise in cancer treatment. The patent, titled '5-HYDROXY-1,4-NAPHTHALENEDIONE FOR USE IN THE TREATMENT OF CANCER,' covers a novel class of compounds that have demonstrated strong inhibitory effects on cancer and cancer stem cells in vitro, particularly against breast and prostate cancer. This development could strengthen the company's position in the pharmaceutical and biotechnology sectors, potentially leading to new collaborations and licensing opportunities in the Chinese market.

15Jul 25

Godavari Biorefineries Secures Chinese Patent for Promising Cancer Treatment Compound

Godavari Biorefineries has been granted a patent by the China National Intellectual Property Administration for a novel compound showing potential in cancer treatment. The patent, titled '5-HYDROXY-1,4-NAPHTHALENEDIONE FOR USE IN THE TREATMENT OF CANCER,' covers compounds that have demonstrated strong inhibitory effects on cancer and cancer stem cells, particularly in breast and prostate cancer. This development marks Godavari Biorefineries' expansion into pharmaceutical research and could open new revenue streams for the company.

07Jul 25

Godavari Biorefineries Secures Anti-Cancer Patent in UK, Spain, and EU Countries

Godavari Biorefineries has received confirmation of its anti-cancer patent in the UK, Spain, and other EU countries. The company is currently conducting clinical trials for this innovative treatment. This development marks a significant expansion beyond the company's traditional biorefinery operations into the pharmaceutical sector, potentially opening new revenue streams and market opportunities.

04Jul 25

Godavari Biorefineries Secures European Patent for Novel Anticancer Molecule, Reports Mixed Financial Results

Godavari Biorefineries obtained a European patent for a novel anticancer molecule, validated in Spain and the UK. Q4 results show a 10.37% increase in net profit to ₹71.93 crore, despite a 5.80% revenue decline. Full-year results reveal a 10.88% revenue growth to ₹1,870.25 crore, but a net loss of ₹23.41 crore.

03Jul 25

Godavari Biorefineries: European Patent Secured for Anticancer Molecule

Godavari Biorefineries has been granted a European patent for a new anti-cancer molecule, validated in Spain, UK, and under the Unitary Patent system. The molecule is described as potent against both cancer and cancer stem cells. This development represents a significant diversification from the company's traditional biorefinery operations and could potentially lead to new revenue streams. In recent financial results, the company reported a 10.37% increase in Q4 net profit to ₹71.93 crore, despite a 5.80% revenue decline. However, full-year results showed a net loss of ₹23.41 crore, with revenue growing 10.88% to ₹1,870.25 crore.

09Apr 25

Godavari Biorefineries Achieves Record 24.65 Lakh Tons of Sugarcane Crushing at Sameerwadi Unit

Godavari Biorefineries Limited's Sameerwadi unit has set a new company record by crushing 24.65 lakh tons of sugarcane, the highest in the company's history. This achievement, announced on April 8, 2025, signifies improved operational capabilities and potentially increased sugar production. The milestone could strengthen the company's position in India's competitive sugar industry, though its impact on financial performance remains to be seen.

08Apr 25

Godavari Biorefineries Hits Record Sugarcane Crushing Milestone at Sameerwadi Unit

Godavari Biorefineries Limited's Sameerwadi unit has set a new company record by crushing over 24.65 lakh tons of sugarcane, as announced on April 8, 2025. This achievement marks the highest crushing volume in the company's history, potentially leading to increased sugar production, improved by-product utilization, and enhanced operational efficiency. The milestone underscores GBL's growing capacity in the sugar industry and could positively impact its market position and financial performance.